Trial Outcomes & Findings for Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML (NCT NCT03922100)
NCT ID: NCT03922100
Last Updated: 2026-03-18
Results Overview
DLTs were classified according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.
Recruitment status
TERMINATED
Study phase
PHASE1/PHASE2
Target enrollment
63 participants
Primary outcome timeframe
From screening to end of first 28-days cycle (47 months)
Results posted on
2026-03-18
Participant Flow
Participant milestones
| Measure |
Phase 1, Schedule A: 20 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 20 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 40 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 40 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 80 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 80 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 120 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 180 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 270 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 270 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 300 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 300 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 360 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 360 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule B: 120 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 180 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 28 consecutive days, in a 28-day cycle.
|
Phase 1, Schedule B: 250 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 250 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 2, Schedule B, Cohort 1:360+150 mg
Participants who had failed standard of care including Venetoclax and Gilteritining based therapies. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
Phase 2, Schedule B, Cohort 2:360+150 mg
Participants who had failed standard of care. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days.
The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
3
|
3
|
3
|
3
|
3
|
4
|
10
|
3
|
4
|
6
|
4
|
5
|
10
|
|
Overall Study
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
3
|
3
|
3
|
3
|
3
|
4
|
10
|
3
|
4
|
6
|
4
|
5
|
10
|
Reasons for withdrawal
| Measure |
Phase 1, Schedule A: 20 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 20 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 40 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 40 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 80 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 80 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 120 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 180 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 270 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 270 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 300 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 300 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 360 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 360 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule B: 120 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 180 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 28 consecutive days, in a 28-day cycle.
|
Phase 1, Schedule B: 250 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 250 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 2, Schedule B, Cohort 1:360+150 mg
Participants who had failed standard of care including Venetoclax and Gilteritining based therapies. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
Phase 2, Schedule B, Cohort 2:360+150 mg
Participants who had failed standard of care. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days.
The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Death
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
1
|
2
|
|
Overall Study
Withdrawal by Subject
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
1
|
0
|
0
|
1
|
|
Overall Study
Study Terminated by Sponsor
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
Overall Study
Disease progression or relapse
|
3
|
2
|
2
|
3
|
2
|
1
|
8
|
1
|
3
|
0
|
2
|
1
|
4
|
|
Overall Study
Adverse Event
|
0
|
0
|
1
|
0
|
0
|
1
|
0
|
0
|
1
|
2
|
0
|
0
|
0
|
|
Overall Study
Physician Decision
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
1
|
0
|
1
|
0
|
|
Overall Study
Eligibility for hemopoietic Stem cell transplantation
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
1
|
|
Overall Study
First cycle dose limiting toxicity
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
0
|
0
|
0
|
|
Overall Study
Unacceptable drug related toxicities Incompatible with Continuation of NMS-03592088
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
Overall Study
Myasthenic syndrome with Systemic and/or bulbar Impairment
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
Baseline Characteristics
Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML
Baseline characteristics by cohort
| Measure |
Phase 1, Schedule A: 20 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 20 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 40 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 40 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 80 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 80 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 120 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 180 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 270 mg
n=4 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 270 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 300 mg
n=10 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 300 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 360 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 360 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule B: 120 mg
n=4 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 180 mg
n=6 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 250 mg
n=4 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 250 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 2, Schedule B, Cohort 1:360+150 mg
n=5 Participants
Participants who had failed standard of care including Venetoclax and Gilteritining based therapies.
NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
Phase 2, Schedule B, Cohort 2: 360+150 mg
n=10 Participants
Participants who had failed standard of care. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days.
The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards
|
Total
n=61 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=110 Participants
|
0 Participants
n=114 Participants
|
0 Participants
n=224 Participants
|
0 Participants
n=104 Participants
|
0 Participants
n=2 Participants
|
0 Participants
n=2 Participants
|
0 Participants
n=14 Participants
|
0 Participants
n=52 Participants
|
0 Participants
n=629 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=22 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
2 Participants
n=110 Participants
|
0 Participants
n=114 Participants
|
2 Participants
n=224 Participants
|
1 Participants
n=104 Participants
|
0 Participants
n=2 Participants
|
3 Participants
n=2 Participants
|
9 Participants
n=14 Participants
|
2 Participants
n=52 Participants
|
2 Participants
n=629 Participants
|
1 Participants
n=3 Participants
|
2 Participants
n=3 Participants
|
2 Participants
n=8 Participants
|
6 Participants
n=6 Participants
|
32 Participants
n=22 Participants
|
|
Age, Categorical
>=65 years
|
1 Participants
n=110 Participants
|
3 Participants
n=114 Participants
|
1 Participants
n=224 Participants
|
2 Participants
n=104 Participants
|
3 Participants
n=2 Participants
|
1 Participants
n=2 Participants
|
1 Participants
n=14 Participants
|
1 Participants
n=52 Participants
|
2 Participants
n=629 Participants
|
5 Participants
n=3 Participants
|
2 Participants
n=3 Participants
|
3 Participants
n=8 Participants
|
4 Participants
n=6 Participants
|
29 Participants
n=22 Participants
|
|
Sex: Female, Male
Female
|
1 Participants
n=110 Participants
|
2 Participants
n=114 Participants
|
2 Participants
n=224 Participants
|
1 Participants
n=104 Participants
|
2 Participants
n=2 Participants
|
1 Participants
n=2 Participants
|
5 Participants
n=14 Participants
|
2 Participants
n=52 Participants
|
2 Participants
n=629 Participants
|
2 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
5 Participants
n=8 Participants
|
5 Participants
n=6 Participants
|
30 Participants
n=22 Participants
|
|
Sex: Female, Male
Male
|
2 Participants
n=110 Participants
|
1 Participants
n=114 Participants
|
1 Participants
n=224 Participants
|
2 Participants
n=104 Participants
|
1 Participants
n=2 Participants
|
3 Participants
n=2 Participants
|
5 Participants
n=14 Participants
|
1 Participants
n=52 Participants
|
2 Participants
n=629 Participants
|
4 Participants
n=3 Participants
|
4 Participants
n=3 Participants
|
0 Participants
n=8 Participants
|
5 Participants
n=6 Participants
|
31 Participants
n=22 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=110 Participants
|
0 Participants
n=114 Participants
|
0 Participants
n=224 Participants
|
0 Participants
n=104 Participants
|
0 Participants
n=2 Participants
|
0 Participants
n=2 Participants
|
0 Participants
n=14 Participants
|
0 Participants
n=52 Participants
|
0 Participants
n=629 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=22 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=110 Participants
|
0 Participants
n=114 Participants
|
0 Participants
n=224 Participants
|
0 Participants
n=104 Participants
|
0 Participants
n=2 Participants
|
0 Participants
n=2 Participants
|
0 Participants
n=14 Participants
|
0 Participants
n=52 Participants
|
0 Participants
n=629 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=22 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=110 Participants
|
0 Participants
n=114 Participants
|
0 Participants
n=224 Participants
|
0 Participants
n=104 Participants
|
0 Participants
n=2 Participants
|
0 Participants
n=2 Participants
|
0 Participants
n=14 Participants
|
0 Participants
n=52 Participants
|
0 Participants
n=629 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=22 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=110 Participants
|
0 Participants
n=114 Participants
|
0 Participants
n=224 Participants
|
0 Participants
n=104 Participants
|
0 Participants
n=2 Participants
|
0 Participants
n=2 Participants
|
0 Participants
n=14 Participants
|
0 Participants
n=52 Participants
|
0 Participants
n=629 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=22 Participants
|
|
Race (NIH/OMB)
White
|
2 Participants
n=110 Participants
|
3 Participants
n=114 Participants
|
3 Participants
n=224 Participants
|
3 Participants
n=104 Participants
|
3 Participants
n=2 Participants
|
4 Participants
n=2 Participants
|
10 Participants
n=14 Participants
|
3 Participants
n=52 Participants
|
4 Participants
n=629 Participants
|
6 Participants
n=3 Participants
|
4 Participants
n=3 Participants
|
4 Participants
n=8 Participants
|
9 Participants
n=6 Participants
|
58 Participants
n=22 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=110 Participants
|
0 Participants
n=114 Participants
|
0 Participants
n=224 Participants
|
0 Participants
n=104 Participants
|
0 Participants
n=2 Participants
|
0 Participants
n=2 Participants
|
0 Participants
n=14 Participants
|
0 Participants
n=52 Participants
|
0 Participants
n=629 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=22 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=110 Participants
|
0 Participants
n=114 Participants
|
0 Participants
n=224 Participants
|
0 Participants
n=104 Participants
|
0 Participants
n=2 Participants
|
0 Participants
n=2 Participants
|
0 Participants
n=14 Participants
|
0 Participants
n=52 Participants
|
0 Participants
n=629 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=6 Participants
|
3 Participants
n=22 Participants
|
|
(Eastern Cooperative Oncology Group Performance Status (ECOG-PS)
ECOG PS = 0
|
0 participants
n=110 Participants
|
1 participants
n=114 Participants
|
1 participants
n=224 Participants
|
0 participants
n=104 Participants
|
3 participants
n=2 Participants
|
2 participants
n=2 Participants
|
4 participants
n=14 Participants
|
0 participants
n=52 Participants
|
3 participants
n=629 Participants
|
2 participants
n=3 Participants
|
2 participants
n=3 Participants
|
1 participants
n=8 Participants
|
4 participants
n=6 Participants
|
23 participants
n=22 Participants
|
|
(Eastern Cooperative Oncology Group Performance Status (ECOG-PS)
ECOG PS = 1
|
3 participants
n=110 Participants
|
2 participants
n=114 Participants
|
2 participants
n=224 Participants
|
3 participants
n=104 Participants
|
0 participants
n=2 Participants
|
1 participants
n=2 Participants
|
5 participants
n=14 Participants
|
3 participants
n=52 Participants
|
1 participants
n=629 Participants
|
4 participants
n=3 Participants
|
1 participants
n=3 Participants
|
2 participants
n=8 Participants
|
5 participants
n=6 Participants
|
32 participants
n=22 Participants
|
|
(Eastern Cooperative Oncology Group Performance Status (ECOG-PS)
ECOG PS = 2
|
0 participants
n=110 Participants
|
0 participants
n=114 Participants
|
0 participants
n=224 Participants
|
0 participants
n=104 Participants
|
0 participants
n=2 Participants
|
1 participants
n=2 Participants
|
1 participants
n=14 Participants
|
0 participants
n=52 Participants
|
0 participants
n=629 Participants
|
0 participants
n=3 Participants
|
1 participants
n=3 Participants
|
2 participants
n=8 Participants
|
1 participants
n=6 Participants
|
6 participants
n=22 Participants
|
PRIMARY outcome
Timeframe: From screening to end of first 28-days cycle (47 months)Population: Participants evaluable for determination of DLT: For each schedule and dose level tested, this population included all participants enrolled in the dose escalation part who received at least 70% of the study drug in the first cycle, unless the reason for non-compliance was drug-related toxicity, and for whom a DLT assessment was available within the DLT window. In case the participant did not fulfill 1 or more of the aforementioned criteria, he/she was to be replaced.
DLTs were classified according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.
Outcome measures
| Measure |
Phase 1, Schedule A: 180 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 20 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 20 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 40 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 40 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 80 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 80 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 120 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 270 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 270 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 300 mg
n=6 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 300 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 360 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 360 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule B: 120 mg
n=3 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 180 mg
n=6 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 28 consecutive days, in a 28-day cycle.
|
Phase 1, Schedule B: 250 mg
n=3 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 250 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 2, Schedule B:360+150 mg
NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
Phase 2, Schedule B, Cohort 2: 360+150 mg
Participants who had failed standard of care. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days.
The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Phase I - Number of Participants With Drug Related First-cycle Dose Limiting Toxicities (DLTs)
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
—
|
PRIMARY outcome
Timeframe: At Screening; Day 1 of Cycle 2 and Cycle 3; and Day 1 at subsequent even cycle; up to End of Treatment visit (within 7 days of the final dose of study drug), up to 17 monthsPopulation: Patients Evaluable for Efficacy Analysis:This population included all enrolled participants in Phase 2 who were treated at RP2D \& had ≥1 hematologic assessment. Participants who had early death or withdrew before response assessment, or had technically suboptimal BM sample, were non-evaluable for response and excluded from efficacy dataset. For Cohort 1 and Cohort 2, only subset of subjects with FLT3-ITD mutation and no D835 mutation based on the central test were included in this population.
CR = complete remission; CRc = composite complete remission rate; CRh = complete remission with partial hematologic recovery, CRi = complete remission with incomplete hematologic recovery; MLFS = morphologic leukemia free state; ORR = overall response rate; SD = stable disease Categories defined by the 2022 European LeukemiaNet (ELN) recommendations.
Outcome measures
| Measure |
Phase 1, Schedule A: 180 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 20 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 20 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 40 mg
n=9 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 40 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 80 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 80 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 120 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 270 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 270 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 300 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 300 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 360 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 360 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule B: 120 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 180 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 28 consecutive days, in a 28-day cycle.
|
Phase 1, Schedule B: 250 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 250 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 2, Schedule B:360+150 mg
NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
Phase 2, Schedule B, Cohort 2: 360+150 mg
Participants who had failed standard of care. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days.
The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Phase II - Number of Participants Who Achieved Composite Complete Remission (CRc) Rate i.e. Complete Remission (CR) + Complete Remission With Incomplete Hematologic Recovery (CRi).
|
—
|
0 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Adverse events were collected from screening visit and assessed up to 18 monthsPopulation: Treated patient population: The treated patient population consists of all enrolled participants who actually receive at least one treatment administration. This population was evaluated in the analysis of patient disposition, baseline characteristics, treatment exposure, efficacy and safety.
TEAE with maximum Common Terminology Criteria (CTC) grade (graded by NCI CTCAE Version 5.0) experienced by each participant is presented. If an AE was reported for a participant more than once during treatment, the worst CTC Grade is presented here. Phase 2 started before Phase 1 completed. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 Life-threatening consequences; urgent intervention indicated.
Outcome measures
| Measure |
Phase 1, Schedule A: 180 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 20 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 20 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 40 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 40 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 80 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 80 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 120 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 270 mg
n=4 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 270 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 300 mg
n=10 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 300 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 360 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 360 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule B: 120 mg
n=4 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 180 mg
n=6 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 28 consecutive days, in a 28-day cycle.
|
Phase 1, Schedule B: 250 mg
n=4 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 250 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 2, Schedule B:360+150 mg
n=15 Participants
NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
Phase 2, Schedule B, Cohort 2: 360+150 mg
Participants who had failed standard of care. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days.
The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Treatment-emergent Adverse Events (TEAEs) Graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] Version 5.0 Criteria
|
3 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
4 Participants
|
10 Participants
|
3 Participants
|
4 Participants
|
6 Participants
|
4 Participants
|
15 Participants
|
—
|
SECONDARY outcome
Timeframe: Schedule A: Day 1 and Day 21 Schedule B: Day 1 and Day 28Population: Participants evaluable for PK analysis (treated participants were considered evaluable if they had sufficient baseline and on-study sampled material to provide interpretable results). The plasma PK of NMS-03592088 and 2 metabolites NMS-03593860 and NMS-03603422 were collected, and PK profile characterised. Schedule A: Day 1 and Day 21 Schedule B: Day 1 and Day 28
Plasma samples were collected and used for pharmacokinetics assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)
Outcome measures
| Measure |
Phase 1, Schedule A: 180 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 20 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 20 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 40 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 40 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 80 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 80 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 120 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 270 mg
n=4 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 270 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 300 mg
n=10 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 300 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 360 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 360 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule B: 120 mg
n=4 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 180 mg
n=6 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 28 consecutive days, in a 28-day cycle.
|
Phase 1, Schedule B: 250 mg
n=4 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 250 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 2, Schedule B:360+150 mg
n=15 Participants
NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
Phase 2, Schedule B, Cohort 2: 360+150 mg
Participants who had failed standard of care. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days.
The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Pharmacokinetic Parameters: Maximum Plasma Concentration (Cmax), Last Measurable Concentration (Clast), and Average Concentration (Cavg) of NMS-03592088
Cmax: Day 1
|
0.118 μM
Standard Deviation 43.9
|
0.00469 μM
Standard Deviation 12.9
|
0.0174 μM
Standard Deviation 19.1
|
0.0262 μM
Standard Deviation 33.6
|
0.0388 μM
Standard Deviation 53.1
|
0.211 μM
Standard Deviation 84.2
|
0.207 μM
Standard Deviation 55.5
|
0.240 μM
Standard Deviation 79.8
|
0.0907 μM
Standard Deviation 82.4
|
0.124 μM
Standard Deviation 42.9
|
0.183 μM
Standard Deviation 51.1
|
0.0995 μM
Standard Deviation 43.9
|
—
|
|
Pharmacokinetic Parameters: Maximum Plasma Concentration (Cmax), Last Measurable Concentration (Clast), and Average Concentration (Cavg) of NMS-03592088
Cmax: Day 21
|
0.320 μM
Standard Deviation 64.0
|
0.0523 μM
Standard Deviation 52.5
|
0.0526 μM
Standard Deviation 32.4
|
0.0896 μM
Standard Deviation 22.6
|
0.125 μM
Standard Deviation 45.9
|
0.553 μM
Standard Deviation 41.9
|
0.444 μM
Standard Deviation 50.6
|
0.467 μM
Standard Deviation 40.9
|
—
|
—
|
—
|
—
|
—
|
|
Pharmacokinetic Parameters: Maximum Plasma Concentration (Cmax), Last Measurable Concentration (Clast), and Average Concentration (Cavg) of NMS-03592088
Cmax: Day 28
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0.266 μM
Standard Deviation 42.0
|
0.354 μM
Standard Deviation 46.5
|
0.462 μM
Standard Deviation 54.4
|
0.168 μM
Standard Deviation 37.7
|
—
|
|
Pharmacokinetic Parameters: Maximum Plasma Concentration (Cmax), Last Measurable Concentration (Clast), and Average Concentration (Cavg) of NMS-03592088
Clast: Day 1
|
0.0309 μM
Standard Deviation 52.3
|
0.00363 μM
Standard Deviation 38.2
|
0.00819 μM
Standard Deviation 55.5
|
0.0132 μM
Standard Deviation 19.0
|
0.0188 μM
Standard Deviation 45.7
|
0.0568 μM
Standard Deviation 46.5
|
0.137 μM
Standard Deviation 68.8
|
0.0930 μM
Standard Deviation 75.7
|
0.0296 μM
Standard Deviation 37.2
|
0.0536 μM
Standard Deviation 79.4
|
0.0957 μM
Standard Deviation 19.7
|
0.0816 μM
Standard Deviation 43.6
|
—
|
|
Pharmacokinetic Parameters: Maximum Plasma Concentration (Cmax), Last Measurable Concentration (Clast), and Average Concentration (Cavg) of NMS-03592088
Clast: Day 21
|
0.0548 μM
Standard Deviation 48.7
|
0.0151 μM
Standard Deviation 59.7
|
0.00902 μM
Standard Deviation 102
|
0.0199 μM
Standard Deviation 77.2
|
0.0230 μM
Standard Deviation 81.4
|
0.0876 μM
Standard Deviation 20.1
|
0.0831 μM
Standard Deviation 86.9
|
0.215 μM
Standard Deviation 80.9
|
—
|
—
|
—
|
—
|
—
|
|
Pharmacokinetic Parameters: Maximum Plasma Concentration (Cmax), Last Measurable Concentration (Clast), and Average Concentration (Cavg) of NMS-03592088
Clast: Day 28
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0.141 μM
Standard Deviation 39.5
|
0.293 μM
Standard Deviation 53.1
|
0.322 μM
Standard Deviation 53.3
|
0.116 μM
Standard Deviation 20.3
|
—
|
|
Pharmacokinetic Parameters: Maximum Plasma Concentration (Cmax), Last Measurable Concentration (Clast), and Average Concentration (Cavg) of NMS-03592088
Cavg: Day 1
|
0.0591 μM
Standard Deviation 65.9
|
0.00385 μM
Standard Deviation 19.9
|
0.0102 μM
Standard Deviation 32.9
|
0.0168 μM
Standard Deviation 22.9
|
0.0230 μM
Standard Deviation 34.1
|
0.0931 μM
Standard Deviation 54.1
|
0.0905 μM
Standard Deviation 61.2
|
0.143 μM
Standard Deviation 78.6
|
0.0455 μM
Standard Deviation 61.5
|
0.0554 μM
Standard Deviation 27.9
|
0.0883 μM
Standard Deviation 61.1
|
0.0172 μM
Standard Deviation 46.4
|
—
|
|
Pharmacokinetic Parameters: Maximum Plasma Concentration (Cmax), Last Measurable Concentration (Clast), and Average Concentration (Cavg) of NMS-03592088
Cavg: Day 21
|
0.200 μM
Standard Deviation 37.3
|
0.0423 μM
Standard Deviation 41.3
|
0.0392 μM
Standard Deviation 56.3
|
0.0740 μM
Standard Deviation 30.2
|
0.0890 μM
Standard Deviation 32.0
|
0.421 μM
Standard Deviation 27.1
|
0.349 μM
Standard Deviation 50.4
|
0.351 μM
Standard Deviation 54.6
|
—
|
—
|
—
|
—
|
—
|
|
Pharmacokinetic Parameters: Maximum Plasma Concentration (Cmax), Last Measurable Concentration (Clast), and Average Concentration (Cavg) of NMS-03592088
Cavg: Day 28
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0.183 μM
Standard Deviation 36.1
|
0.277 μM
Standard Deviation 48.2
|
0.378 μM
Standard Deviation 56.2
|
0.118 μM
Standard Deviation 69.8
|
—
|
SECONDARY outcome
Timeframe: Schedule A: Day 1 and 21 Schedule B: Day 1 and 28Population: Participants evaluable for PK analysis (participants with sufficient samples to provide interpretable results). The plasma PK of NMS-03592088 and NMS-03593860 and NMS-03603422 were collected for PK profile. Schedule B involved 28 days continuous treatment. Last sampling time was 24 hrs after dosing on day 1 \& 28. This limited sampling times didn't allow calculation of t½, of the terminal phase, characterised by long half-lives, shown by data from schedule A. Hence evaluation was not performed.
Plasma samples were collected and used for pharmacokinetics (PK) assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)
Outcome measures
| Measure |
Phase 1, Schedule A: 180 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 20 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 20 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 40 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 40 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 80 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 80 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 120 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 270 mg
n=4 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 270 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 300 mg
n=10 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 300 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 360 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 360 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule B: 120 mg
n=4 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 180 mg
n=6 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 28 consecutive days, in a 28-day cycle.
|
Phase 1, Schedule B: 250 mg
n=4 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 250 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 2, Schedule B:360+150 mg
n=15 Participants
NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
Phase 2, Schedule B, Cohort 2: 360+150 mg
Participants who had failed standard of care. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days.
The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Pharmacokinetic Parameters: Time to Maximum Plasma Concentration (Tmax), Time to Last Measurable Concentration (Tlast), and Terminal Elimination Half-life (t½,z) of NMS-03592088
Tmax: Day 1
|
1.67 hour
Standard Deviation 35.0
|
6.00 hour
Standard Deviation 0
|
3.33 hour
Standard Deviation 69.3
|
10.4 hour
Standard Deviation 90.4
|
3.01 hour
Standard Deviation 87.7
|
3.02 hour
Standard Deviation 65.8
|
3.78 hour
Standard Deviation 41.7
|
4.66 hour
Standard Deviation 24.4
|
4.00 hour
Standard Deviation 57.7
|
3.65 hour
Standard Deviation 41.7
|
3.25 hour
Standard Deviation 83.9
|
2.73 hour
Standard Deviation 46.5
|
—
|
|
Pharmacokinetic Parameters: Time to Maximum Plasma Concentration (Tmax), Time to Last Measurable Concentration (Tlast), and Terminal Elimination Half-life (t½,z) of NMS-03592088
Tmax: Day 21
|
9.31 hour
Standard Deviation 136
|
1.67 hour
Standard Deviation 125
|
3.00 hour
Standard Deviation 88.2
|
4.00 hour
Standard Deviation 50.0
|
3.33 hour
Standard Deviation 69.3
|
4.00 hour
Standard Deviation 44.7
|
5.41 hour
Standard Deviation 108
|
4.41 hour
Standard Deviation 37.7
|
—
|
—
|
—
|
—
|
—
|
|
Pharmacokinetic Parameters: Time to Maximum Plasma Concentration (Tmax), Time to Last Measurable Concentration (Tlast), and Terminal Elimination Half-life (t½,z) of NMS-03592088
Tmax: Day 28
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
2.33 hour
Standard Deviation 58.6
|
6.00 hour
Standard Deviation 49.5
|
2.80 hour
Standard Deviation 63.9
|
4.33 hour
Standard Deviation 34.7
|
—
|
|
Pharmacokinetic Parameters: Time to Maximum Plasma Concentration (Tmax), Time to Last Measurable Concentration (Tlast), and Terminal Elimination Half-life (t½,z) of NMS-03592088
Tlast: Day 1
|
22.6 hour
Standard Deviation 13.0
|
23.5 hour
Standard Deviation 1.05
|
22.5 hour
Standard Deviation 3.23
|
21.1 hour
Standard Deviation 11.9
|
22.7 hour
Standard Deviation 7.15
|
23.4 hour
Standard Deviation 2.14
|
16.4 hour
Standard Deviation 50.6
|
22.4 hour
Standard Deviation 6.78
|
23.2 hour
Standard Deviation 2.79
|
20.0 hour
Standard Deviation 34.8
|
18.5 hour
Standard Deviation 45.6
|
5.96 hour
Standard Deviation 1.29
|
—
|
|
Pharmacokinetic Parameters: Time to Maximum Plasma Concentration (Tmax), Time to Last Measurable Concentration (Tlast), and Terminal Elimination Half-life (t½,z) of NMS-03592088
Tlast: Day 21
|
120 hour
Standard Deviation 39.7
|
160 hour
Standard Deviation 35.2
|
194 hour
Standard Deviation 0.998
|
170 hour
Standard Deviation 25.4
|
170 hour
Standard Deviation 43.8
|
160 hour
Standard Deviation 31.1
|
183 hour
Standard Deviation 26.6
|
120 hour
Standard Deviation 60.2
|
—
|
—
|
—
|
—
|
—
|
|
Pharmacokinetic Parameters: Time to Maximum Plasma Concentration (Tmax), Time to Last Measurable Concentration (Tlast), and Terminal Elimination Half-life (t½,z) of NMS-03592088
Tlast: Day 28
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
24.0 hour
Standard Deviation 0
|
22.0 hour
Standard Deviation 22.8
|
24.0 hour
Standard Deviation 0.309
|
17.9 hour
Standard Deviation 57.5
|
—
|
|
Pharmacokinetic Parameters: Time to Maximum Plasma Concentration (Tmax), Time to Last Measurable Concentration (Tlast), and Terminal Elimination Half-life (t½,z) of NMS-03592088
t½,z: Day 1
|
NA hour
Standard Deviation NA
Last sampling time was 24 hrs after dosing on day 1 \& 28. This limited sampling times didn't allow calculation of t½, of the terminal phase, characterised by long half-lives, shown by data from schedule A. Hence evaluation was not performed.
|
NA hour
Standard Deviation NA
Last sampling time was 24 hrs after dosing on day 1 \& 28. This limited sampling times didn't allow calculation of t½, of the terminal phase, characterised by long half-lives, shown by data from schedule A. Hence evaluation was not performed.
|
NA hour
Standard Deviation NA
Last sampling time was 24 hrs after dosing on day 1 \& 28. This limited sampling times didn't allow calculation of t½, of the terminal phase, characterised by long half-lives, shown by data from schedule A. Hence evaluation was not performed.
|
NA hour
Standard Deviation NA
Last sampling time was 24 hrs after dosing on day 1 \& 28. This limited sampling times didn't allow calculation of t½, of the terminal phase, characterised by long half-lives, shown by data from schedule A. Hence evaluation was not performed.
|
NA hour
Standard Deviation NA
Last sampling time was 24 hrs after dosing on day 1 \& 28. This limited sampling times didn't allow calculation of t½, of the terminal phase, characterised by long half-lives, shown by data from schedule A. Hence evaluation was not performed.
|
NA hour
Standard Deviation NA
Last sampling time was 24 hrs after dosing on day 1 \& 28. This limited sampling times didn't allow calculation of t½, of the terminal phase, characterised by long half-lives, shown by data from schedule A. Hence evaluation was not performed.
|
NA hour
Standard Deviation NA
Last sampling time was 24 hrs after dosing on day 1 \& 28. This limited sampling times didn't allow calculation of t½, of the terminal phase, characterised by long half-lives, shown by data from schedule A. Hence evaluation was not performed.
|
NA hour
Standard Deviation NA
Last sampling time was 24 hrs after dosing on day 1 \& 28. This limited sampling times didn't allow calculation of t½, of the terminal phase, characterised by long half-lives, shown by data from schedule A. Hence evaluation was not performed.
|
NA hour
Standard Deviation NA
Last sampling time was 24 hrs after dosing on day 1 \& 28. This limited sampling times didn't allow calculation of t½, of the terminal phase, characterised by long half-lives, shown by data from schedule A. Hence evaluation was not performed.
|
NA hour
Standard Deviation NA
Last sampling time was 24 hrs after dosing on day 1 \& 28. This limited sampling times didn't allow calculation of t½, of the terminal phase, characterised by long half-lives, shown by data from schedule A. Hence evaluation was not performed.
|
NA hour
Standard Deviation NA
Last sampling time was 24 hrs after dosing on day 1 \& 28. This limited sampling times didn't allow calculation of t½, of the terminal phase, characterised by long half-lives, shown by data from schedule A. Hence evaluation was not performed.
|
NA hour
Standard Deviation NA
Last sampling time was 24 hrs after dosing on day 1 \& 28. This limited sampling times didn't allow calculation of t½, of the terminal phase, characterised by long half-lives, shown by data from schedule A. Hence evaluation was not performed.
|
—
|
|
Pharmacokinetic Parameters: Time to Maximum Plasma Concentration (Tmax), Time to Last Measurable Concentration (Tlast), and Terminal Elimination Half-life (t½,z) of NMS-03592088
t½,z: Day 21
|
57.3 hour
Standard Deviation 32.3
|
89.5 hour
Standard Deviation 19.5
|
79.5 hour
Standard Deviation 35.2
|
71.7 hour
Standard Deviation 4.35
|
68.4 hour
Standard Deviation 18.2
|
63.7 hour
Standard Deviation 24.0
|
77.3 hour
Standard Deviation 16.4
|
150 hour
Standard Deviation 0
|
—
|
—
|
—
|
—
|
—
|
|
Pharmacokinetic Parameters: Time to Maximum Plasma Concentration (Tmax), Time to Last Measurable Concentration (Tlast), and Terminal Elimination Half-life (t½,z) of NMS-03592088
t½,z: Day 28
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
NA hour
Standard Deviation NA
Last sampling time was 24 hrs after dosing on day 1 \& 28. This limited sampling times didn't allow calculation of t½, of the terminal phase, characterised by long half-lives, shown by data from schedule A. Hence evaluation was not performed.
|
NA hour
Standard Deviation NA
Last sampling time was 24 hrs after dosing on day 1 \& 28. This limited sampling times didn't allow calculation of t½, of the terminal phase, characterised by long half-lives, shown by data from schedule A. Hence evaluation was not performed.
|
NA hour
Standard Deviation NA
Last sampling time was 24 hrs after dosing on day 1 \& 28. This limited sampling times didn't allow calculation of t½, of the terminal phase, characterised by long half-lives, shown by data from schedule A. Hence evaluation was not performed.
|
NA hour
Standard Deviation NA
Last sampling time was 24 hrs after dosing on day 1 \& 28. This limited sampling times didn't allow calculation of t½, of the terminal phase, characterised by long half-lives, shown by data from schedule A. Hence evaluation was not performed.
|
—
|
SECONDARY outcome
Timeframe: Schedule A: Day 1 and Day 21 Schedule B: Day 1 and Day 28Population: Participants evaluable for PK analysis (treated participants were considered evaluable if they had sufficient baseline and on-study sampled material to provide interpretable results). The plasma PK of NMS-03592088 and 2 metabolites NMS-03593860 and NMS-03603422 were collected, and PK profile characterised. Schedule A: Day 1 and Day 21 Schedule B: Day 1 and Day 28
Plasma samples were collected and used for pharmacokinetics (PK) assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)
Outcome measures
| Measure |
Phase 1, Schedule A: 180 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 20 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 20 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 40 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 40 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 80 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 80 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 120 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 270 mg
n=4 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 270 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 300 mg
n=10 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 300 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 360 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 360 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule B: 120 mg
n=4 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 180 mg
n=6 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 28 consecutive days, in a 28-day cycle.
|
Phase 1, Schedule B: 250 mg
n=4 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 250 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 2, Schedule B:360+150 mg
n=15 Participants
NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
Phase 2, Schedule B, Cohort 2: 360+150 mg
Participants who had failed standard of care. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days.
The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Pharmacokinetic Parameter: Area Under the Concentration-time Curve to the Last Measurable Concentration (AUClast) and Area Under the Concentration-time Curve From Time Zero to 24 Hour (AUC0-24) of NMS-03592088
AUClast: Day 1
|
1.43 h·μM
Standard Deviation 66.7
|
0.0923 h·μM
Standard Deviation 19.9
|
0.244 h·μM
Standard Deviation 32.9
|
0.402 h·μM
Standard Deviation 22.9
|
0.551 h·μM
Standard Deviation 34.1
|
2.23 h·μM
Standard Deviation 54.1
|
2.17 h·μM
Standard Deviation 61.2
|
3.44 h·μM
Standard Deviation 78.6
|
1.09 h·μM
Standard Deviation 61.5
|
1.33 h·μM
Standard Deviation 27.9
|
2.12 h·μM
Standard Deviation 60.8
|
0.412 h·μM
Standard Deviation 46.4
|
—
|
|
Pharmacokinetic Parameter: Area Under the Concentration-time Curve to the Last Measurable Concentration (AUClast) and Area Under the Concentration-time Curve From Time Zero to 24 Hour (AUC0-24) of NMS-03592088
AUClast: Day 21
|
13.4 h·μM
Standard Deviation 54.4
|
4.10 h·μM
Standard Deviation 53.3
|
3.96 h·μM
Standard Deviation 71.9
|
6.31 h·μM
Standard Deviation 29.0
|
6.98 h·μM
Standard Deviation 35.3
|
34.5 h·μM
Standard Deviation 28.2
|
31.4 h·μM
Standard Deviation 59.1
|
23.7 h·μM
Standard Deviation 80.1
|
—
|
—
|
—
|
—
|
—
|
|
Pharmacokinetic Parameter: Area Under the Concentration-time Curve to the Last Measurable Concentration (AUClast) and Area Under the Concentration-time Curve From Time Zero to 24 Hour (AUC0-24) of NMS-03592088
AUClast: Day 28
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
4.39 h·μM
Standard Deviation 36.1
|
6.67 h·μM
Standard Deviation 48.7
|
9.09 h·μM
Standard Deviation 56.5
|
2.84 h·μM
Standard Deviation 69.9
|
—
|
|
Pharmacokinetic Parameter: Area Under the Concentration-time Curve to the Last Measurable Concentration (AUClast) and Area Under the Concentration-time Curve From Time Zero to 24 Hour (AUC0-24) of NMS-03592088
AUC0-24: Day 1
|
1.42 h·μM
Standard Deviation 65.9
|
0.0923 h·μM
Standard Deviation 19.9
|
0.244 h·μM
Standard Deviation 32.9
|
0.402 h·μM
Standard Deviation 22.9
|
0.551 h·μM
Standard Deviation 34.1
|
2.23 h·μM
Standard Deviation 54.1
|
2.17 h·μM
Standard Deviation 61.2
|
3.44 h·μM
Standard Deviation 78.6
|
1.09 h·μM
Standard Deviation 61.5
|
1.33 h·μM
Standard Deviation 27.9
|
2.12 h·μM
Standard Deviation 61.1
|
0.412 h·μM
Standard Deviation 46.4
|
—
|
|
Pharmacokinetic Parameter: Area Under the Concentration-time Curve to the Last Measurable Concentration (AUClast) and Area Under the Concentration-time Curve From Time Zero to 24 Hour (AUC0-24) of NMS-03592088
AUC0-24: Day 21
|
4.80 h·μM
Standard Deviation 37.3
|
1.02 h·μM
Standard Deviation 41.3
|
0.941 h·μM
Standard Deviation 56.3
|
1.78 h·μM
Standard Deviation 30.2
|
2.14 h·μM
Standard Deviation 32.0
|
10.1 h·μM
Standard Deviation 27.1
|
8.37 h·μM
Standard Deviation 50.4
|
8.43 h·μM
Standard Deviation 54.6
|
—
|
—
|
—
|
—
|
—
|
|
Pharmacokinetic Parameter: Area Under the Concentration-time Curve to the Last Measurable Concentration (AUClast) and Area Under the Concentration-time Curve From Time Zero to 24 Hour (AUC0-24) of NMS-03592088
AUC0-24: Day 28
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
4.39 h·μM
Standard Deviation 36.1
|
6.65 h·μM
Standard Deviation 48.2
|
9.07 h·μM
Standard Deviation 56.2
|
2.83 h·μM
Standard Deviation 69.8
|
—
|
SECONDARY outcome
Timeframe: Schedule A: Day 21Population: Participants evaluable for PK analysis (participants with sufficient samples to provide interpretable results). The plasma PK of NMS-03592088 and NMS-03593860 and NMS-03603422 were collected for PK profile. The half-life of the molecule was many times longer than 24 hours, so it was not possible to estimate it at all for Schedule B due to the 24-hour sampling. Therefore, parameters V/F, Vss/F could not be calculated.
Plasma samples were collected and used for pharmacokinetics (PK) assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)
Outcome measures
| Measure |
Phase 1, Schedule A: 180 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 20 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 20 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 40 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 40 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 80 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 80 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 120 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 270 mg
n=4 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 270 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 300 mg
n=10 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 300 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 360 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 360 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule B: 120 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 180 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 28 consecutive days, in a 28-day cycle.
|
Phase 1, Schedule B: 250 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 250 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 2, Schedule B:360+150 mg
NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
Phase 2, Schedule B, Cohort 2: 360+150 mg
Participants who had failed standard of care. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days.
The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Pharmacokinetic Parameters: Apparent Volume of Distribution (V/F) and Apparent Volume of Distribution at Steady State (Vss/F)
V/F: Day 21
|
1630 L
Standard Deviation 31.0
|
844 L
Standard Deviation 32.5
|
2030 L
Standard Deviation 39.7
|
1940 L
Standard Deviation 31.3
|
2680 L
Standard Deviation 50.9
|
1070 L
Standard Deviation 17.5
|
1770 L
Standard Deviation 36.0
|
1070 L
Standard Deviation 0
|
—
|
—
|
—
|
—
|
—
|
|
Pharmacokinetic Parameters: Apparent Volume of Distribution (V/F) and Apparent Volume of Distribution at Steady State (Vss/F)
Vss/F: Day 21
|
5810 L
Standard Deviation 25.8
|
4880 L
Standard Deviation 21.8
|
9440 L
Standard Deviation 20.3
|
8800 L
Standard Deviation 22.8
|
10900 L
Standard Deviation 39.4
|
4710 L
Standard Deviation 37.0
|
8270 L
Standard Deviation 37.0
|
10500 L
Standard Deviation 0
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Schedule A: Day 1 and Day 21 Schedule B: Day 1 and Day 28 CL/F: Evaluation of CL/F for Day 1 of all arms in Schedule A and Schedule B and Day 28 of Schedule B has not been performedPopulation: Participants evaluable for PK analysis (participants with sufficient samples to provide interpretable results). The plasma PK of NMS-03592088 and NMS-03593860 and NMS-03603422 were collected for PK profile. The half-life of the molecule was many times longer than 24 hours, so it was not possible to estimate it at all for Schedule B due to the 24-hour sampling. This implied that the parameter CL/F could not be calculated
Plasma samples were collected and used for pharmacokinetics (PK) assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)
Outcome measures
| Measure |
Phase 1, Schedule A: 180 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 20 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 20 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 40 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 40 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 80 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 80 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 120 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 270 mg
n=4 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 270 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 300 mg
n=10 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 300 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 360 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 360 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule B: 120 mg
n=4 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 180 mg
n=6 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 28 consecutive days, in a 28-day cycle.
|
Phase 1, Schedule B: 250 mg
n=4 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 250 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 2, Schedule B:360+150 mg
n=15 Participants
NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
Phase 2, Schedule B, Cohort 2: 360+150 mg
Participants who had failed standard of care. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days.
The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Pharmacokinetic Parameters: Apparent Plasma Clearance (CL/F) and Apparent Plasma Clearance at Steady State (CLss/F)
CLss/F: Day 1
|
301 L/h
Standard Deviation 57.5
|
399 L/h
Standard Deviation 19.9
|
318 L/h
Standard Deviation 32.2
|
372 L/h
Standard Deviation 23.3
|
434 L/h
Standard Deviation 41.6
|
264 L/h
Standard Deviation 44.7
|
477 L/h
Standard Deviation 117
|
502 L/h
Standard Deviation 126
|
317 L/h
Standard Deviation 89.3
|
263 L/h
Standard Deviation 31.4
|
359 L/h
Standard Deviation 97.1
|
1820 L/h
Standard Deviation 45.0
|
—
|
|
Pharmacokinetic Parameters: Apparent Plasma Clearance (CL/F) and Apparent Plasma Clearance at Steady State (CLss/F)
CL/F: Day 1
|
NA L/h
Standard Deviation NA
The half-life of the molecule was many times longer than 24h so it was not possible to estimate it at all for Schedule B due to the 24h sampling. This implied that the parameter CL/F could not be calculated
|
NA L/h
Standard Deviation NA
The half-life of the molecule was many times longer than 24h so it was not possible to estimate it at all for Schedule B due to the 24h sampling. This implied that the parameter CL/F could not be calculated
|
NA L/h
Standard Deviation NA
The half-life of the molecule was many times longer than 24h so it was not possible to estimate it at all for Schedule B due to the 24h sampling. This implied that the parameter CL/F could not be calculated
|
NA L/h
Standard Deviation NA
The half-life of the molecule was many times longer than 24h so it was not possible to estimate it at all for Schedule B due to the 24h sampling. This implied that the parameter CL/F could not be calculated
|
NA L/h
Standard Deviation NA
The half-life of the molecule was many times longer than 24h so it was not possible to estimate it at all for Schedule B due to the 24h sampling. This implied that the parameter CL/F could not be calculated
|
NA L/h
Standard Deviation NA
The half-life of the molecule was many times longer than 24h so it was not possible to estimate it at all for Schedule B due to the 24h sampling. This implied that the parameter CL/F could not be calculated
|
NA L/h
Standard Deviation NA
The half-life of the molecule was many times longer than 24h so it was not possible to estimate it at all for Schedule B due to the 24h sampling. This implied that the parameter CL/F could not be calculated
|
NA L/h
Standard Deviation NA
The half-life of the molecule was many times longer than 24h so it was not possible to estimate it at all for Schedule B due to the 24h sampling. This implied that the parameter CL/F could not be calculated
|
NA L/h
Standard Deviation NA
The half-life of the molecule was many times longer than 24h so it was not possible to estimate it at all for Schedule B due to the 24h sampling. This implied that the parameter CL/F could not be calculated
|
NA L/h
Standard Deviation NA
The half-life of the molecule was many times longer than 24h so it was not possible to estimate it at all for Schedule B due to the 24h sampling. This implied that the parameter CL/F could not be calculated
|
NA L/h
Standard Deviation NA
The half-life of the molecule was many times longer than 24h so it was not possible to estimate it at all for Schedule B due to the 24h sampling. This implied that the parameter CL/F could not be calculated
|
NA L/h
Standard Deviation NA
The half-life of the molecule was many times longer than 24h so it was not possible to estimate it at all for Schedule B due to the 24h sampling. This implied that the parameter CL/F could not be calculated
|
—
|
|
Pharmacokinetic Parameters: Apparent Plasma Clearance (CL/F) and Apparent Plasma Clearance at Steady State (CLss/F)
CL/F: Day 21
|
21.4 L/h
Standard Deviation 46.5
|
7.02 L/h
Standard Deviation 53.1
|
20.4 L/h
Standard Deviation 57.1
|
19.0 L/h
Standard Deviation 34.6
|
27.6 L/h
Standard Deviation 52.5
|
12.1 L/h
Standard Deviation 26.3
|
16.8 L/h
Standard Deviation 46.5
|
4.94 L/h
Standard Deviation 0
|
—
|
—
|
—
|
—
|
—
|
|
Pharmacokinetic Parameters: Apparent Plasma Clearance (CL/F) and Apparent Plasma Clearance at Steady State (CLss/F)
CL/F: Day 28
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
NA L/h
Standard Deviation NA
The half-life of the molecule was many times longer than 24h so it was not possible to estimate it at all for Schedule B due to the 24h sampling. This implied that the parameter CL/F could not be calculated
|
NA L/h
Standard Deviation NA
The half-life of the molecule was many times longer than 24h so it was not possible to estimate it at all for Schedule B due to the 24h sampling. This implied that the parameter CL/F could not be calculated
|
NA L/h
Standard Deviation NA
The half-life of the molecule was many times longer than 24h so it was not possible to estimate it at all for Schedule B due to the 24h sampling. This implied that the parameter CL/F could not be calculated
|
NA L/h
Standard Deviation NA
The half-life of the molecule was many times longer than 24h so it was not possible to estimate it at all for Schedule B due to the 24h sampling. This implied that the parameter CL/F could not be calculated
|
—
|
|
Pharmacokinetic Parameters: Apparent Plasma Clearance (CL/F) and Apparent Plasma Clearance at Steady State (CLss/F)
CLss/F: Day 21
|
74.7 L/h
Standard Deviation 38.7
|
39.9 L/h
Standard Deviation 40.8
|
91.2 L/h
Standard Deviation 42.5
|
85.7 L/h
Standard Deviation 26.3
|
110 L/h
Standard Deviation 38.6
|
50.9 L/h
Standard Deviation 23.1
|
77.8 L/h
Standard Deviation 38.4
|
98.2 L/h
Standard Deviation 50.4
|
—
|
—
|
—
|
—
|
—
|
|
Pharmacokinetic Parameters: Apparent Plasma Clearance (CL/F) and Apparent Plasma Clearance at Steady State (CLss/F)
CLss/F: Day 28
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
57.4 L/h
Standard Deviation 46.8
|
56.3 L/h
Standard Deviation 35.5
|
63.8 L/h
Standard Deviation 52.7
|
209 L/h
Standard Deviation 117
|
—
|
SECONDARY outcome
Timeframe: Schedule A: Day 21 Schedule B: Day 28 Evaluation of Accumulation ratios (RA) for AUC0-24 and Cmax on Day 1 of all arms in Schedule A and Schedule B has not been performed.Population: Participants evaluable for PK analysis (treated participants were considered evaluable if they had sufficient baseline and on-study sampled material to provide interpretable results). The plasma PK of NMS-03592088 and 2 metabolites NMS-03593860 and NMS-03603422 were collected, and PK profile characterised. Schedule A: Day 21 Schedule B: Day 28 Evaluation of Accumulation ratios (RA) for AUC0-24 and Cmax on Day 1 of all arms in Schedule A and Schedule B has not been performed.
Plasma samples were collected and used for pharmacokinetics assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%).
Outcome measures
| Measure |
Phase 1, Schedule A: 180 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 20 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 20 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 40 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 40 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 80 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 80 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 120 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 270 mg
n=4 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 270 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 300 mg
n=10 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 300 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 360 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 360 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule B: 120 mg
n=4 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 180 mg
n=6 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 28 consecutive days, in a 28-day cycle.
|
Phase 1, Schedule B: 250 mg
n=4 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 250 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 2, Schedule B:360+150 mg
n=15 Participants
NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
Phase 2, Schedule B, Cohort 2: 360+150 mg
Participants who had failed standard of care. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days.
The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Pharmacokinetic Parameters: Accumulation Ratios (RA) for AUC0-24 and Cmax
RA, AUC0-24: Day 21
|
4.14 Ratio
Standard Deviation 50.2
|
8.99 Ratio
Standard Deviation 46.9
|
3.72 Ratio
Standard Deviation 26.0
|
4.42 Ratio
Standard Deviation 18.3
|
3.91 Ratio
Standard Deviation 9.88
|
4.48 Ratio
Standard Deviation 32.1
|
5.78 Ratio
Standard Deviation 85.6
|
4.92 Ratio
Standard Deviation 66.0
|
—
|
—
|
—
|
—
|
—
|
|
Pharmacokinetic Parameters: Accumulation Ratios (RA) for AUC0-24 and Cmax
RA, AUC0-24: Day 28
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
6.14 Ratio
Standard Deviation 33.9
|
5.81 Ratio
Standard Deviation 42.9
|
3.40 Ratio
Standard Deviation 36.9
|
9.33 Ratio
Standard Deviation 85.5
|
—
|
|
Pharmacokinetic Parameters: Accumulation Ratios (RA) for AUC0-24 and Cmax
RA, Cmax: Day 21
|
2.86 Ratio
Standard Deviation 69.4
|
8.26 Ratio
Standard Deviation 49.1
|
3.08 Ratio
Standard Deviation 33.7
|
3.74 Ratio
Standard Deviation 42.5
|
3.54 Ratio
Standard Deviation 38.4
|
3.07 Ratio
Standard Deviation 59.3
|
2.73 Ratio
Standard Deviation 52.5
|
4.06 Ratio
Standard Deviation 69.0
|
—
|
—
|
—
|
—
|
—
|
|
Pharmacokinetic Parameters: Accumulation Ratios (RA) for AUC0-24 and Cmax
RA, Cmax: Day 28
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
6.19 Ratio
Standard Deviation 44.4
|
3.75 Ratio
Standard Deviation 55.3
|
2.59 Ratio
Standard Deviation 29.6
|
2.13 Ratio
Standard Deviation 70.7
|
—
|
SECONDARY outcome
Timeframe: Schedule A: Day 21 Schedule B: Day 28 Evaluation of Fraction excreted unchanged (FE) for Arms 20, 40, 80, 120 and 180 mg of Schedule A and Arm 360+150 mg of Schedule B has not been performed.Population: Participants evaluable for PK analysis (participants with sufficient samples to provide interpretable results). The PK of NMS-03592088, NMS-03593860 \& NMS-03603422 were collected. Urine was collected in all participants enrolled starting from the dose level 6 (Schedule A) or the first dose level (Schedule B). Per protocol this assessment was performed only during the Phase I of the study hence data not available for Phase 2 and for first 5 dose levels of Schedule A (20-180 mg).
Urine samples were collected and used for pharmacokinetics (PK) assessments. Only cohorts with available data are presented. The assessment was performed only during the Phase I of the study. Mean values of PK parameters are presented with the coefficient of variation (CV%)
Outcome measures
| Measure |
Phase 1, Schedule A: 180 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 20 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 20 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 40 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 40 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 80 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 80 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 120 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 270 mg
n=4 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 270 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 300 mg
n=10 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 300 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 360 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 360 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule B: 120 mg
n=4 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 180 mg
n=6 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 28 consecutive days, in a 28-day cycle.
|
Phase 1, Schedule B: 250 mg
n=4 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 250 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 2, Schedule B:360+150 mg
NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
Phase 2, Schedule B, Cohort 2: 360+150 mg
Participants who had failed standard of care. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days.
The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Pharmacokinetic Parameters: Fraction Excreted Unchanged (FE) of NMS-03592088
Day 21
|
—
|
—
|
—
|
—
|
—
|
0.0321 percentage
Standard Deviation 76.4
|
0.0396 percentage
Standard Deviation 137
|
0.0812 percentage
Standard Deviation 49.4
|
—
|
—
|
—
|
—
|
—
|
|
Pharmacokinetic Parameters: Fraction Excreted Unchanged (FE) of NMS-03592088
Day 28
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0.0301 percentage
Standard Deviation 42.2
|
0.0577 percentage
Standard Deviation 67.4
|
0.0299 percentage
Standard Deviation 44.9
|
—
|
—
|
SECONDARY outcome
Timeframe: From the date of treatment initiation up to end of study (approximately 1.5 years)Population: Participants with AML FLT3 mutation based on local assessment based on efficacy dataset (Participants evaluable for efficacy analysis): This population consisted of all enrolled Participants in the Phase II who were treated at the recommended Phase II dose (RP2D) and had ≥1 on-treatment hematologic assessment(s) (ie, they must have had adequate BM response evaluation).
For participants with AML diagnosis the number and percentage of participants with best response achieved on treatment in the following categories: CR, CRi, CRh, PR, MLFS, SD, No Response and Progressive Disease (PD). CR= complete response; CRh= Complete Remission with Partial Hematologic Recovery, CRi= Complete Remission with Incomplete Hematologic Recovery; CRc= Complete Remission Rate; MLFS= Morphologic leukemia free state; ORR= Overall Response Rate; PR= Partial Remission; SD= Stable Disease
Outcome measures
| Measure |
Phase 1, Schedule A: 180 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 20 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 20 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 40 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 40 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 80 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 80 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 120 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 270 mg
n=4 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 270 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 300 mg
n=10 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 300 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 360 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 360 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule B: 120 mg
n=4 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 180 mg
n=6 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 28 consecutive days, in a 28-day cycle.
|
Phase 1, Schedule B: 250 mg
n=4 Participants
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 250 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 2, Schedule B:360+150 mg
n=5 Participants
NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
Phase 2, Schedule B, Cohort 2: 360+150 mg
n=10 Participants
Participants who had failed standard of care. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days.
The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Best Response Rate for Participants With Acute Myeloblastic Leukemia (AML).
No Response/SD
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
4 Participants
|
6 Participants
|
4 Participants
|
3 Participants
|
6 Participants
|
|
Best Response Rate for Participants With Acute Myeloblastic Leukemia (AML).
CRc: CR + CRi
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Best Response Rate for Participants With Acute Myeloblastic Leukemia (AML).
CR+CRh+CRi
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Best Response Rate for Participants With Acute Myeloblastic Leukemia (AML).
ORR:CR+CRh+CRi+MLFS+PR
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
|
Best Response Rate for Participants With Acute Myeloblastic Leukemia (AML).
CRi
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Best Response Rate for Participants With Acute Myeloblastic Leukemia (AML).
MLFS
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: From the date of first response up to end of study (approximately 1.5 years)Population: Patients evaluable for efficacy analysis (efficacy dataset):For Cohort 1 and Cohort 2, only the subset of participants with FLT3-ITD mutation and no D835 mutation based on the central test were included in this population.
Number of participants who achieved a CR as Best Response.
Outcome measures
| Measure |
Phase 1, Schedule A: 180 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 20 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 20 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 40 mg
n=9 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 40 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 80 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 80 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 120 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 270 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 270 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 300 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 300 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 360 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 360 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule B: 120 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 180 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 28 consecutive days, in a 28-day cycle.
|
Phase 1, Schedule B: 250 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 250 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 2, Schedule B:360+150 mg
NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
Phase 2, Schedule B, Cohort 2: 360+150 mg
Participants who had failed standard of care. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days.
The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
For AML and in Phase II Only: Number of Participants Who Achieved Complete Remission (CR)
|
—
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: From the date of first response up to end of study (approximately 1.5 years)Population: Patients evaluable for efficacy analysis (efficacy dataset):For Cohort 1 and Cohort 2, only the subset of participants with FLT3-ITD mutation and no D835 mutation based on the central test were included in this population.
Defined as the number of participants who achieved a CR or CRh or CRi as best response, divided by the number of participants in the analysis population.
Outcome measures
| Measure |
Phase 1, Schedule A: 180 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 20 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 20 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 40 mg
n=9 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 40 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 80 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 80 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 120 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 270 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 270 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 300 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 300 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 360 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 360 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule B: 120 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 180 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 28 consecutive days, in a 28-day cycle.
|
Phase 1, Schedule B: 250 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 250 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 2, Schedule B:360+150 mg
NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
Phase 2, Schedule B, Cohort 2: 360+150 mg
Participants who had failed standard of care. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days.
The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
For AML and in Phase II Only: Complete Remission and Complete Remission With Partial Hematologic Recovery (CR/CRh) Rate
|
—
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: From the date of first response up to end of study (approximately 1.5 years)Population: Patients evaluable for efficacy analysis (efficacy dataset):For Cohort 1 and Cohort 2, only the subset of participants with FLT3-ITD mutation and no D835 mutation based on the central test were included in this population
Defined as the number of participants who achieved CRi or MLFS as best response, divided by the number of participants in the analysis population.
Outcome measures
| Measure |
Phase 1, Schedule A: 180 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 20 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 20 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 40 mg
n=9 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 40 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 80 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 80 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 120 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 270 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 270 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 300 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 300 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 360 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 360 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule B: 120 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 180 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 28 consecutive days, in a 28-day cycle.
|
Phase 1, Schedule B: 250 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 250 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 2, Schedule B:360+150 mg
NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
Phase 2, Schedule B, Cohort 2: 360+150 mg
Participants who had failed standard of care. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days.
The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
For AML and in Phase II Only: Overall Response Rate (ORR: CRc + CRh + MLFS + PR)
|
—
|
0 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: From the date of first response up to end of study (approximately 1.5 years)Population: Patients evaluable for efficacy analysis (efficacy dataset):For Cohort 1 and Cohort 2, only the subset of participants with FLT3-ITD mutation and no D835 mutation based on the central test were included in this population
Defined as proportion of participants bridged to hemopoietic stem cell transplantation
Outcome measures
| Measure |
Phase 1, Schedule A: 180 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 20 mg
n=3 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 20 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 40 mg
n=9 Participants
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 40 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 80 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 80 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 120 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 270 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 270 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 300 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 300 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 360 mg
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 360 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule B: 120 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 180 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 28 consecutive days, in a 28-day cycle.
|
Phase 1, Schedule B: 250 mg
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 250 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 2, Schedule B:360+150 mg
NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
Phase 2, Schedule B, Cohort 2: 360+150 mg
Participants who had failed standard of care. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days.
The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Rate of Participants Bridged To Hemopoietic Stem Cell Transplantation
|
—
|
0 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
Adverse Events
Phase 1, Schedule A: 20 mg
Serious events: 0 serious events
Other events: 3 other events
Deaths: 3 deaths
Phase 1, Schedule A: 40 mg
Serious events: 2 serious events
Other events: 3 other events
Deaths: 3 deaths
Phase 1, Schedule A: 80 mg
Serious events: 2 serious events
Other events: 3 other events
Deaths: 3 deaths
Phase 1, Schedule A: 120 mg
Serious events: 0 serious events
Other events: 3 other events
Deaths: 3 deaths
Phase 1, Schedule A: 180 mg
Serious events: 2 serious events
Other events: 3 other events
Deaths: 3 deaths
Phase 1, Schedule A: 270 mg
Serious events: 3 serious events
Other events: 4 other events
Deaths: 4 deaths
Phase 1, Schedule A: 300 mg
Serious events: 8 serious events
Other events: 10 other events
Deaths: 9 deaths
Phase 1, Schedule A: 360 mg
Serious events: 3 serious events
Other events: 3 other events
Deaths: 3 deaths
Phase 1, Schedule B: 120 mg
Serious events: 4 serious events
Other events: 4 other events
Deaths: 4 deaths
Phase 1, Schedule B: 180 mg
Serious events: 6 serious events
Other events: 6 other events
Deaths: 6 deaths
Phase 1, Schedule B: 250 mg
Serious events: 4 serious events
Other events: 3 other events
Deaths: 4 deaths
Phase 2, Schedule B: 360-150 mg
Serious events: 14 serious events
Other events: 14 other events
Deaths: 9 deaths
Serious adverse events
| Measure |
Phase 1, Schedule A: 20 mg
n=3 participants at risk
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 20 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 40 mg
n=3 participants at risk
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 40 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 80 mg
n=3 participants at risk
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 80 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 120 mg
n=3 participants at risk
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 180 mg
n=3 participants at risk
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 270 mg
n=4 participants at risk
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 270 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 300 mg
n=10 participants at risk
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 300 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 360 mg
n=3 participants at risk
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 360 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule B: 120 mg
n=4 participants at risk
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 180 mg
n=6 participants at risk
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 250 mg
n=4 participants at risk
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 250 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 2, Schedule B: 360-150 mg
n=15 participants at risk
* Participants who have failed standard of care including Venetoclax and Gilteritining based therapies
* Participants who have failed standard of care.
NMS-03592088 will be administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) will be administered from Cycle 2 onwards.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Nervous system disorders
Haemorrhage intracranial
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Nervous system disorders
Myasthenic syndrome
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
20.0%
2/10 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
2/6 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
26.7%
4/15 • Number of events 4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Blood and lymphatic system disorders
Haemorrhagic diathesis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Cardiac disorders
Cardiac arrest
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Eye disorders
Diplopia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Gingival bleeding
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Upper gastrointestinal haemorrhage
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
50.0%
2/4 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
13.3%
2/15 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
General disorders
Decreased activity
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
General disorders
Disease progression
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
50.0%
2/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
General disorders
Pyrexia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Bronchopulmonary aspergillosis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Clostridium difficile colitis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Corona virus infection
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Lung infection
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
20.0%
2/10 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Osteomyelitis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Pharyngitis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
13.3%
2/15 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Pseudomonal sepsis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Sepsis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
26.7%
4/15 • Number of events 5 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Septic shock
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Staphylococcal sepsis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Injury, poisoning and procedural complications
Accidental overdose
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Musculoskeletal and connective tissue disorders
Posture abnormal
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Nervous system disorders
Cerebral haemorrhage
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Nervous system disorders
Myasthenia gravis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Nervous system disorders
Neurotoxicity
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Respiratory, thoracic and mediastinal disorders
Lung infiltration
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
13.3%
2/15 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Eye disorders
Eyelid ptosis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Incarcerated umbilical hernia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Vascular disorders
Haematoma
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
13.3%
2/15 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Blood and lymphatic system disorders
Febrile bone marrow aplasia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Blood and lymphatic system disorders
Leukopenia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Gastric haemorrhage
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
COVID-19
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Device related infection
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Enterocolitis infectious
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Escherichia bacteraemia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Kidney infection
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Pyelonephritis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Injury, poisoning and procedural complications
Femur fracture
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Respiratory, thoracic and mediastinal disorders
Laryngeal haemorrhage
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Respiratory, thoracic and mediastinal disorders
Lung disorder
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Skin and subcutaneous tissue disorders
Ecchymosis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Hepatobiliary disorders
Cholecystitis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Pneumonia klebsiella
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Pneumonia viral
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Skin infection
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Wound infection
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
General disorders
General physical health deterioration
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
Other adverse events
| Measure |
Phase 1, Schedule A: 20 mg
n=3 participants at risk
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 20 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle.
|
Phase 1, Schedule A: 40 mg
n=3 participants at risk
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 40 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 80 mg
n=3 participants at risk
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 80 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 120 mg
n=3 participants at risk
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 180 mg
n=3 participants at risk
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 270 mg
n=4 participants at risk
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 270 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 300 mg
n=10 participants at risk
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 300 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule A: 360 mg
n=3 participants at risk
All participants in Phase I, Schedule A, who received NMS-03592088 at the starting dose of 360 mg administered orally once daily for 21 consecutive days followed by 7 days of rest in a 28-day cycle
|
Phase 1, Schedule B: 120 mg
n=4 participants at risk
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 120 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 180 mg
n=6 participants at risk
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 180 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 1, Schedule B: 250 mg
n=4 participants at risk
All participants in Phase I, Schedule B, who received NMS-03592088 at the starting dose of 250 mg administered orally once daily for 28 consecutive days, in a 28-day cycle
|
Phase 2, Schedule B: 360-150 mg
n=15 participants at risk
* Participants who have failed standard of care including Venetoclax and Gilteritining based therapies
* Participants who have failed standard of care.
NMS-03592088 will be administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) will be administered from Cycle 2 onwards.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Nervous system disorders
Headache
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Nervous system disorders
Neurotoxicity
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Nervous system disorders
Tremor
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
20.0%
2/10 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
20.0%
2/10 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
General disorders
Pain
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
30.0%
3/10 • Number of events 6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 5 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
13.3%
2/15 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Skin and subcutaneous tissue disorders
Decubitus ulcer
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Vascular disorders
Haematoma
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Vascular disorders
Hypertension
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
2/6 • Number of events 4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Vascular disorders
Hypotension
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Anal fissure
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Colitis ischaemic
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Blood and lymphatic system disorders
Anaemia
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
100.0%
3/3 • Number of events 14 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
50.0%
2/4 • Number of events 9 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
20.0%
2/10 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
2/6 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Blood and lymphatic system disorders
Haemorrhagic diathesis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Blood and lymphatic system disorders
Leukocytosis
|
66.7%
2/3 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
50.0%
2/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Blood and lymphatic system disorders
Pancytopenia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
50.0%
2/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
2/6 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
13.3%
2/15 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Eye disorders
Conjunctival haemorrhage
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Abdominal pain
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
66.7%
2/3 • Number of events 5 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Angina bullosa haemorrhagica
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
13.3%
2/15 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
20.0%
2/10 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
2/6 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
5/15 • Number of events 7 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Gingival bleeding
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
50.0%
2/4 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Gingival hypertrophy
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Haemorrhoidal haemorrhage
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Lower gastrointestinal haemorrhage
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Melaena
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Mouth haemorrhage
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Nausea
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 5 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
50.0%
2/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
40.0%
4/10 • Number of events 7 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
50.0%
2/4 • Number of events 5 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
2/6 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
40.0%
6/15 • Number of events 6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Oral blood blister
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Proctalgia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
50.0%
2/4 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
40.0%
4/10 • Number of events 9 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
5/15 • Number of events 32 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
General disorders
Asthenia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 5 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
50.0%
2/4 • Number of events 5 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
50.0%
5/10 • Number of events 6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
75.0%
3/4 • Number of events 4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
50.0%
2/4 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
13.3%
2/15 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
General disorders
Fatigue
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
General disorders
Mucosal inflammation
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
General disorders
Oedema peripheral
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
2/6 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
13.3%
2/15 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
General disorders
Pyrexia
|
66.7%
2/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 5 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
100.0%
3/3 • Number of events 4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
50.0%
2/4 • Number of events 4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
2/6 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
75.0%
3/4 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
5/15 • Number of events 9 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Hepatobiliary disorders
Cholecystitis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 5 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Bronchopulmonary aspergillosis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Conjunctivitis
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Corona virus infection
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
20.0%
2/10 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Lung infection
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
20.0%
2/10 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Sepsis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
13.3%
2/15 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
Alanine aminotransferase increased
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
Amylase increased
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
Aspartate aminotransferase increased
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
20.0%
2/10 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
2/6 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
20.0%
2/10 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
13.3%
2/15 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
Blood creatinine increased
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
Blood phosphorus decreased
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
Electrocardiogram QT prolonged
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
Lipase increased
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
Platelet count decreased
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
50.0%
2/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
50.0%
2/4 • Number of events 4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
20.0%
3/15 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Metabolism and nutrition disorders
Hyperphosphataemia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
100.0%
3/3 • Number of events 5 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
20.0%
2/10 • Number of events 5 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
13.3%
2/15 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
66.7%
2/3 • Number of events 4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
13.3%
2/15 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Eye disorders
Diplopia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Musculoskeletal and connective tissue disorders
Pain in jaw
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
13.3%
2/15 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Eye disorders
Dry eye
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
General disorders
Oedema
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Hepatobiliary disorders
Hypertransaminasaemia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Pneumonia klebsiella
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Rhinitis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Injury, poisoning and procedural complications
Head injury
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Injury, poisoning and procedural complications
Muscle injury
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
Activated partial thromboplastin time prolonged
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
Antithrombin III decreased
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
Oxygen saturation decreased
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
Weight increased
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder neoplasm
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Nervous system disorders
Syncope
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Renal and urinary disorders
Ureterolithiasis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Reproductive system and breast disorders
Balanoposthitis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Reproductive system and breast disorders
Perineal pain
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Vascular disorders
Haemorrhage
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Vascular disorders
Thrombophlebitis superficial
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Eye disorders
Eyelid oedema
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Aphthous ulcer
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Oral purpura
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
General disorders
Catheter site haematoma
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Clostridium difficile colitis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Orchitis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Pyelonephritis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Renal abscess
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Soft tissue infection
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Injury, poisoning and procedural complications
Procedural pain
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
Bilirubin conjugated increased
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Metabolism and nutrition disorders
Cell death
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Metabolism and nutrition disorders
Magnesium deficiency
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Nervous system disorders
Haemorrhage intracranial
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Nervous system disorders
Myasthenic syndrome
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
13.3%
2/15 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Renal and urinary disorders
Polyuria
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Reproductive system and breast disorders
Vaginal haemorrhage
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Reproductive system and breast disorders
Vulval disorder
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Respiratory, thoracic and mediastinal disorders
Pharyngeal haematoma
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Skin and subcutaneous tissue disorders
Acute febrile neutrophilic dermatosis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Skin and subcutaneous tissue disorders
Skin lesion
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer haemorrhage
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Vascular disorders
Phlebitis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Vascular disorders
Venous thrombosis limb
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
Blood lactate dehydrogenase increased
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Blood and lymphatic system disorders
Hyperleukocytosis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Injury, poisoning and procedural complications
Intentional underdose
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Blood and lymphatic system disorders
Lymph node pain
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
Blood phosphorus increased
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Blood and lymphatic system disorders
Splenic infarction
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Ear and labyrinth disorders
Ear pain
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Gingival pain
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Stomatitis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
General disorders
Chest pain
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
General disorders
Implant site haemorrhage
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Hepatobiliary disorders
Hepatomegaly
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Oral herpes
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Injury, poisoning and procedural complications
Febrile nonhaemolytic transfusion reaction
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Musculoskeletal and connective tissue disorders
Groin pain
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour inflammation
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Nervous system disorders
Depressed level of consciousness
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Renal and urinary disorders
Azotaemia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Renal and urinary disorders
Oliguria
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Reproductive system and breast disorders
Genital swelling
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Skin and subcutaneous tissue disorders
Capillaritis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Skin and subcutaneous tissue disorders
Pain of skin
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Eye disorders
Lacrimation increased
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
Urine output decreased
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Psychiatric disorders
Agitation
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Renal and urinary disorders
Renal colic
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Respiratory, thoracic and mediastinal disorders
Tachypnoea
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Skin and subcutaneous tissue disorders
Blood blister
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Skin and subcutaneous tissue disorders
Ecchymosis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Retching
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
Blood fibrinogen decreased
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Skin and subcutaneous tissue disorders
Purpura
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Cardiac disorders
Ventricular extrasystoles
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Eye disorders
Eye oedema
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Eye disorders
Eyelid ptosis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Eye disorders
Ocular hyperaemia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Odynophagia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Tongue ulceration
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Upper gastrointestinal haemorrhage
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
General disorders
Device related thrombosis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
General disorders
Mucosal haemorrhage
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Liver abscess
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Oral candidiasis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Skin infection
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Metabolism and nutrition disorders
Tumour lysis syndrome
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Musculoskeletal and connective tissue disorders
Myositis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Musculoskeletal and connective tissue disorders
Tendon pain
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Product Issues
Device occlusion
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Renal and urinary disorders
Urinary tract discomfort
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchospasm
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Skin and subcutaneous tissue disorders
Hair colour changes
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Skin and subcutaneous tissue disorders
Petechiae
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Dieulafoy's vascular malformation
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Dermatitis infected
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Respiratory, thoracic and mediastinal disorders
Orthopnoea
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Cardiac disorders
Palpitations
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
General disorders
General physical health deterioration
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Localised infection
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
Myeloblast count increased
|
33.3%
1/3 • Number of events 3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Investigations
International normalised ratio increased
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Reproductive system and breast disorders
Pelvic pain
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Psychiatric disorders
Depression
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Immune system disorders
Drug hypersensitivity
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
General disorders
Decreased activity
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Musculoskeletal and connective tissue disorders
Posture abnormal
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
33.3%
1/3 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Nervous system disorders
Myasthenia gravis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
10.0%
1/10 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/15 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/10 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/3 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/6 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
0.00%
0/4 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
6.7%
1/15 • Number of events 1 • Adverse events were collected from screening visit and assessed up to 18 months
Adverse events (AEs) were assessed and documented at each scheduled clinic visit from signing Informed Consent until 42 days after last on-study treatment administration, or until all serious or study drug-related toxicities had resolved or determined to be "chronic" or "stable," whichever came first, or until alternative anticancer therapy was initiated. Reporting period ended at the time new treatment started.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.
- Publication restrictions are in place
Restriction type: OTHER